Orange Book product · Generic (ANDA)
PIPERACILLIN AND TAZOBACTAM
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
At a glance
Mar 22, 2017
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 22, 2017
9 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
Strength
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 206996
Product number
003
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
Yes
Active-ingredient family
View full familyGeneric (ANDA) of PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
- 2025PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINERBrand (NDA)
NDA 206056 · B BRAUN MEDICAL
- 1998ZOSYN IN PLASTIC CONTAINERBrand (NDA)
NDA 050750 · BAXTER HLTHCARE CORP
- 1993ZOSYNBrand (NDA)
NDA 050684 · WYETH PHARMS
- 2023PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 217409 · EUGIA PHARMA
- 2023PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 217243 · SHANDONG
- 2021PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 208674 · SAGENT PHARMS INC
- 2021PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 208675 · SAGENT PHARMS INC
- 2019PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 212287 · ASTRAL
- 2018PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 204959 · SHANDONG
- 2018PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 203719 · FRESENIUS KABI
- 2018PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 203720 · FRESENIUS KABI
- 2018PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 206204 · FRESENIUS KABI USA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
